Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Fate Therapeutics, Inc.

< Previous 1 2 Next >
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics to Present at Upcoming Investor Conferences
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE NBIX
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics to Present at Upcoming Investor Conferences
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Announces Leadership Transition
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics to Present at Upcoming December Investor Conferences
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback